MedicalWebPage + FAQPage + Article + Drug

Vivitrol is the brand name for extended-release naltrexone, an FDA-approved monthly injection used to treat opioid use disorder and alcohol use disorder. It is one of the three medications considered gold standard for medication-assisted treatment (MAT).
If you are in Virginia weighing your MAT options, this guide explains what Vivitrol actually is, how it works in the brain, who qualifies, what the risks are, and what it costs in Hampton Roads.
Vivitrol is a 380 milligram intramuscular injection administered once every 4 weeks. It is manufactured by Alkermes and has been FDA-approved for opioid use disorder since 2010 and alcohol use disorder since 2006.
The active ingredient is naltrexone in an extended-release polymer. After injection, naltrexone releases steadily into the bloodstream over approximately 28 to 30 days. Blood levels remain relatively stable throughout the month, which is the main advantage over daily oral naltrexone (ReVia).
The injection is given in the gluteal muscle by a licensed provider. Most patients tolerate the injection well. Some experience mild soreness at the injection site for a few days.
Vivitrol works by binding to the brain's mu-opioid receptors. When naltrexone occupies these receptors, opioids like heroin, oxycodone, or fentanyl cannot bind. The euphoria that reinforces continued use does not happen.
For alcohol, the mechanism is related but not identical. Alcohol triggers endorphin release in the brain's reward system. Endorphins bind to mu-opioid receptors. Vivitrol blocks this reinforcement pathway, which reduces alcohol cravings and heavy drinking.
The clinical result: on Vivitrol, using opioids produces no high, and drinking alcohol produces significantly less reward. The brain has less reason to seek out either substance.
Vivitrol works well for specific patient profiles:
Vivitrol is not the right first choice for patients still using opioids, patients unable to complete a detox period, or patients with severe chronic pain requiring opioid pain management.
This is the most critical clinical point. Vivitrol requires 7 to 14 days completely opioid-free before the first injection.
Starting Vivitrol while any opioids are still in the system causes precipitated withdrawal. The naltrexone displaces opioids from receptors and blocks them. The result is sudden, severe withdrawal that can last hours to days. This is one of the worst experiences in addiction medicine.
Providers use a urine drug screen before administering Vivitrol. Some providers also use a naloxone challenge test to verify no opioids remain in the system. If you have used long-acting opioids like methadone or fentanyl, the washout period may need to be longer than 14 days.
Naltrexone is available in two forms:
Vivitrol (monthly injection). Consistent blood levels for 28 days. No daily adherence required. Administered by a provider. Cannot be missed accidentally.
Oral naltrexone (ReVia, generic). Daily 50 milligram tablet. Requires daily patient adherence. Less consistent blood levels. Significantly less expensive.
Research consistently shows better adherence and lower relapse rates with the monthly injection than with the daily pill. This is not because the medication is different. It is because monthly dosing eliminates the daily decision of whether to take the medication.
Oral naltrexone can still be a reasonable choice for patients with strong adherence support or cost concerns. Vivitrol is generally considered the first-line naltrexone option when accessible.
Vivitrol is widely available at licensed MAT providers, specialty pharmacies, and some primary care offices throughout Hampton Roads.
Retail cost is approximately 1,500 to 1,700 dollars per monthly dose without insurance. However, coverage and support programs significantly reduce this:
If you are considering Vivitrol for opioid or alcohol use disorder in Hampton Roads, call a licensed MAT provider for a free assessment. Insurance verification usually takes minutes. The medication saves lives.
If you’re ready to explore your options — or just want to ask questions — reach out today. We’ll guide you with clarity, compassion, and confidence.
or message us directly through our website
You don’t have to figure this out alone. Let’s take the next step — together.
Vivitrol is the brand name for extended-release naltrexone, an FDA-approved monthly intramuscular injection used to treat opioid use disorder and alcohol use disorder. Each 380 milligram injection provides approximately 28 days of steady medication. Vivitrol is manufactured by Alkermes and is not a controlled substance.
Vivitrol binds to the brain's mu-opioid receptors and blocks them. Opioids like heroin, oxycodone, or fentanyl cannot bind while naltrexone is present, so they cannot produce a high. For alcohol, Vivitrol blocks the endorphin reward pathway that reinforces heavy drinking. Both effects reduce cravings and reduce the reinforcement that drives continued use.
Vivitrol is a monthly injection administered by a provider. Oral naltrexone (ReVia and generic) is a daily 50 milligram tablet taken by the patient. Vivitrol provides more consistent blood levels and eliminates daily adherence decisions. Research shows better adherence and lower relapse rates with the monthly injection compared to the daily pill.
Vivitrol works well for patients who have completed medical detox and are opioid-free for 7 to 14 days, patients who prefer monthly injections over daily medication, patients with co-occurring alcohol use disorder, patients in professions where controlled substances create licensure concerns, and patients transitioning out of residential treatment or drug court programs.
Yes. Vivitrol requires 7 to 14 days completely opioid-free before the first injection. Starting Vivitrol while any opioids remain in the system causes severe precipitated withdrawal. Providers use urine drug screens and sometimes a naloxone challenge test to verify readiness. Long-acting opioids like methadone or fentanyl may require longer washout periods.
Common side effects include nausea (especially early), headache, fatigue, injection-site reactions, and elevated liver enzymes. The most important safety warning is post-treatment overdose risk. Tolerance drops sharply while on Vivitrol. If a patient relapses at pre-treatment doses, the result is often fatal overdose. Never combine Vivitrol with opioid pain medications.
Retail cost is approximately 1,500 to 1,700 dollars per monthly dose without insurance. Virginia Medicaid (Cardinal Care) covers Vivitrol with no out-of-pocket cost. Tricare covers it for military beneficiaries. Most major commercial insurers cover it under Virginia Code § 38.2-3412.1. The Alkermes Vivitrol Co-Pay Program can reduce cost to as little as 5 dollars per dose for eligible commercially insured patients.
There is no maximum recommended duration. Many patients remain on Vivitrol for a year or longer. Some transition off after 12 to 24 months of stability. The decision to discontinue is individual and should be made with your MAT provider. Discontinuing Vivitrol carries a significant relapse and overdose risk if the underlying addiction is not adequately addressed.
Yes. Vivitrol is FDA-approved for both opioid use disorder and alcohol use disorder. Clinical trials show significant reductions in heavy drinking days and increased abstinence rates. Vivitrol works particularly well for patients with co-occurring opioid and alcohol use disorders. Suboxone is approved only for opioid use disorder, not alcohol.
Find out how long MAT treatment lasts in Virginia, what determines your duration, when tapering is appropriate, and how Bold Recovery structures your medication timeline.
Compare the best outpatient rehab in Virginia with this 2026 decision guide. Levels of care, costs, accreditation, and red flags to avoid. Start your search.
Virginia insurers denied 25.6% of SUD claims in 2024. Step-by-step appeal guide using MHPAEA and Virginia § 38.2-3412.1. Get rehab coverage approved.